Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention -: Principal results of a prospective randomized controlled study (MOSES)
Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention -: Principal results of a prospective randomized controlled study (MOSES)
复制标题
DOI：
10.1161/01.str.0000166048.35740.a9
复制
发表时间：
2005-06-01
期刊：
影响因子：
8.3
通讯作者：
Diener, HC
中科院分区：
文献类型：
--
作者：
Schrader, J;L端ders, S;Diener, HC
背景和目的——在高血压脑卒中患者中，在血压控制水平相同的情况下，依普罗沙坦比尼群地平更能有效降低脑血管和心血管疾病的发病率和死亡率。方法——过去24个月内（经脑部计算机断层扫描或核磁共振证实）总共1405名明确的高危高血压患者随机接受依普罗沙坦或尼群地平治疗（平均随访时间） 2.5 年）。主要终点是总死亡率和所有心脑血管事件（包括所有复发事件）的复合终点。结果-随机化成功，基线特征没有显着差异。在整个研究期间，两组之间的血压降低到相当的程度，没有任何显着差异（依普罗沙坦和尼群地平治疗分别为150.7/84 mm Hg和152.0/87.2 mm Hg，通过动态血压监测证实分别降至137.5/80.8 mm Hg和136.0/80.2 mm Hg）。此外，3 个月后，血压平均值已达到正常值，75.5% 的人达到了该值
Background and Purpose-In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality.Methods-A total of 1405 well-defined, high-risk hypertensives with cerebral event during the last 24 months ( proven by cerebral computed tomography scan or nuclear magnetic resonance) were randomized to eprosartan or nitrendipine (mean follow-up 2.5 years). Primary end point was the composite of total mortality and all cardiovascular and cerebrovascular events, including all recurrent events.Results-Randomization was successful without significant differences in the baseline characteristics. Blood pressure was reduced to a comparable extent without any significant differences between the 2 groups during the whole study period (150.7/84 mm Hg and 152.0/87.2 mm Hg with eprosartan and nitrendipine therapy to 137.5/80.8 mm Hg and 136.0/80.2 mm Hg, respectively, confirmed by ambulatory blood pressure monitoring). Moreover, already after 3 months, normotensive mean values were achieved, and 75.5% reached values